Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TYRA-200 in Intrahepatic cholangiocarcinoma , Cancer. The expected timing is based on the latest available company guidance and may change.
BEACH301 trial. 10/28/24- IND cleared. 8/21/25- First participant dosed. Initial results from safety sentinel cohort in H2 2026. 11/05/25:- BEACH301 Phase 2 study is enrolling the safety sentinel cohort and remains on track to report interim results from this cohort in H2 2026. 03/02/26:- BEACH301 sentinel cohort enrolling; two of four doses cleared safely; interim height data expected 2H 2026. 05/13/26:- BEACH301 safety sentinel cohort enrolled; four dose levels cleared; initial results expected Q4 2026. 08/04/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.